Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia

  • Vega-Garcia, Nerea
  • Benito, Rocío
  • Esperanza-Cebollada, Elena
  • Llop, Marta
  • Robledo, Cristina
  • Vicente-Garcés, Clara
  • Ortega Blanco, Margarita
Leucèmia limfoblàstica aguda infantil; Seqüenciació de nova generació, Leucemia linfoblástica aguda infantil; Secuenciación de nueva generación, Childhood acute lymphoblastic leukemia; Next-generation sequencing, The development of Next-Generation Sequencing (NGS) has provided useful diagnostic, prognostic, and therapeutic strategies for individualized management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Consequently, NGS is rapidly being established in clinical practice. However, the technology’s complexity, bioinformatics analysis, and the different available options difficult a broad consensus between different laboratories in its daily routine introduction. This collaborative study among Spanish centers was aimed to assess the feasibility, pros, and cons of our customized panel and other commercial alternatives of NGS-targeted approaches. The custom panel was tested in three different sequencing centers. We used the same samples to assess other commercial panels (OncomineTM Childhood Cancer Research Assay; Archer®FusionPlex® ALL, and Human Comprehensive Cancer Panel GeneRead Panel v2®). Overall, the panels showed a good performance in different centers and platforms, but each NGS approach presented some issues, as well as pros and cons. Moreover, a previous consensus on the analysis and reporting following international guidelines would be preferable to improve the concordance in results among centers. Our study shows the challenges posed by NGS methodology and the need to consider several aspects of the chosen NGS-targeted approach and reach a consensus before implementing it in daily practice., This study has been supported by a grant from “Fundación Unoentrecienmil”; grants from Instituto de Salud Carlos III (PI12/02417; PI16/00246; PI12/00816; PI16CIII/00026; PI16/0665); Asociación Pablo Ugarte (TPY-M 1149/13; TRPV 205/18), ASION (TVP 141/17); Fundación Sonrisa de Alex & Todos somos Iván (TVP 1324/15); Consejería de Educación, Junta de Castilla y León (SA271P18); Fondos FEDER (CIBERONC [CB16/12/00284]), Proyectos de Investigación del SACYL, GRS 1847/A/18, Generalitat Valenciana GV2019/077 and Fundación AMPILE. J.M.H.S. is supported with a research grant by FEHH (“Fundación Española de Hematología y Hemoterapia”), A.M. a grant from Junta provincial de Salamanca de la Asociación Española Contra el Cáncer (AECC), and M.M. holds the grant “Ayuda predoctoral de la Junta de Castilla y León” by the Fondo Social Europeo (JCYL-EDU/556/2019 Ph.D. scholarship).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia

  • Vega-Garcia, Nerea
  • Benito, Rocío|||0000-0001-9781-4198
  • Esperanza-Cebollada, Elena|||0000-0001-5451-0370
  • Llop, Marta
  • Robledo, Cristina|||0000-0003-0445-3210
  • Vicente-Garcés, Clara|||0000-0002-2556-043X
  • Alonso, Javier|||0000-0002-6287-8391
  • Barragán, Eva
  • Fernández, Guerau
  • Hernández-Sánchez, Jesús M.
  • Martín-Izquierdo, Marta
  • Maynou, Joan
  • Minguela, Alfredo|||0000-0003-2472-5893
  • Montaño, Adrián|||0000-0002-3178-6726
  • Ortega, Margarita
  • Torrebadell, Montserrat
  • Cervera, José|||0000-0001-8252-1106
  • Sánchez, Joaquín
  • Jiménez-Velasco, Antonio|||0000-0001-6421-7872
  • Riesco, Susana
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • Lassaletta, Álvaro|||0000-0003-2881-1473
  • Fernández, José María
  • Rives, Susana|||0000-0002-5658-1831
  • Dapena, José Luis|||0000-0002-6711-7479
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Camós, Mireia|||0000-0003-3658-7942
The development of Next-Generation Sequencing (NGS) has provided useful diagnostic, prognostic, and therapeutic strategies for individualized management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Consequently, NGS is rapidly being established in clinical practice. However, the technology's complexity, bioinformatics analysis, and the different available options difficult a broad consensus between different laboratories in its daily routine introduction. This collaborative study among Spanish centers was aimed to assess the feasibility, pros, and cons of our customized panel and other commercial alternatives of NGS-targeted approaches. The custom panel was tested in three different sequencing centers. We used the same samples to assess other commercial panels (Oncomine TM Childhood Cancer Research Assay; Archer ® FusionPlex ® ALL, and Human Comprehensive Cancer Panel GeneRead Panel v2 ®). Overall, the panels showed a good performance in different centers and platforms, but each NGS approach presented some issues, as well as pros and cons. Moreover, a previous consensus on the analysis and reporting following international guidelines would be preferable to improve the concordance in results among centers. Our study shows the challenges posed by NGS methodology and the need to consider several aspects of the chosen NGS-targeted approach and reach a consensus before implementing it in daily practice.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia

  • Vega-Garcia, Nerea
  • Benito, Rocío
  • Esperanza-Cebollada, Elena
  • Llop, Marta
  • Robledo, Cristina
  • Vicente-Garcés, Clara
  • Ortega Blanco, Margarita
Leucèmia limfoblàstica aguda infantil; Seqüenciació de nova generació, Leucemia linfoblástica aguda infantil; Secuenciación de nueva generación, Childhood acute lymphoblastic leukemia; Next-generation sequencing, The development of Next-Generation Sequencing (NGS) has provided useful diagnostic, prognostic, and therapeutic strategies for individualized management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Consequently, NGS is rapidly being established in clinical practice. However, the technology’s complexity, bioinformatics analysis, and the different available options difficult a broad consensus between different laboratories in its daily routine introduction. This collaborative study among Spanish centers was aimed to assess the feasibility, pros, and cons of our customized panel and other commercial alternatives of NGS-targeted approaches. The custom panel was tested in three different sequencing centers. We used the same samples to assess other commercial panels (OncomineTM Childhood Cancer Research Assay; Archer®FusionPlex® ALL, and Human Comprehensive Cancer Panel GeneRead Panel v2®). Overall, the panels showed a good performance in different centers and platforms, but each NGS approach presented some issues, as well as pros and cons. Moreover, a previous consensus on the analysis and reporting following international guidelines would be preferable to improve the concordance in results among centers. Our study shows the challenges posed by NGS methodology and the need to consider several aspects of the chosen NGS-targeted approach and reach a consensus before implementing it in daily practice., This study has been supported by a grant from “Fundación Unoentrecienmil”; grants from Instituto de Salud Carlos III (PI12/02417; PI16/00246; PI12/00816; PI16CIII/00026; PI16/0665); Asociación Pablo Ugarte (TPY-M 1149/13; TRPV 205/18), ASION (TVP 141/17); Fundación Sonrisa de Alex & Todos somos Iván (TVP 1324/15); Consejería de Educación, Junta de Castilla y León (SA271P18); Fondos FEDER (CIBERONC [CB16/12/00284]), Proyectos de Investigación del SACYL, GRS 1847/A/18, Generalitat Valenciana GV2019/077 and Fundación AMPILE. J.M.H.S. is supported with a research grant by FEHH (“Fundación Española de Hematología y Hemoterapia”), A.M. a grant from Junta provincial de Salamanca de la Asociación Española Contra el Cáncer (AECC), and M.M. holds the grant “Ayuda predoctoral de la Junta de Castilla y León” by the Fondo Social Europeo (JCYL-EDU/556/2019 Ph.D. scholarship).